Depo-Provera Lawsuit Updates and Information

If you’re considering a Depo-Provera lawsuit, Nguyen Injury Lawyer can provide the latest information on these claims. We will explain the legal process and discuss potential Depo-Provera settlement amounts.

Recent scientific research has revealed a potential link between Depo-Provera use and the development of brain tumors. Women who used Depo-Provera and were later diagnosed with a meningioma may be eligible to file a lawsuit seeking financial compensation. This evidence is fueling a growing number of Depo-Provera lawsuits across the country.

Our attorneys are currently consulting with numerous women each week who used Depo-Provera and subsequently received a meningioma diagnosis. Nguyen Injury Lawyer is dedicated to representing women in these cases, specifically those who received at least two injections and were later diagnosed with a meningioma brain tumor. If you meet these criteria, we can simplify the process of joining this litigation. Contact our Depo-Provera lawyers today at XXX-XXX-XXXX or through our online contact page: https://www.nguyeninjurylawyer.com/contact.

Table of Contents

• Depo Provera Lawsuit FAQs
• Evidence Linking Depo Provera to Brain Tumors
• Projected Depo Provera Settlement Amounts
• Deadline for Depo Provera Lawsuits
• Contact Us About a Depo Provera Compensation Claim

Depo Provera Lawsuit News and Updates for 2026

Nguyen Injury Lawyer has been involved in the Depo-Provera litigation from the beginning and is committed to providing victims with up-to-date information. We anticipate that this Depo-Provera lawsuit will progress through the MDL (Multidistrict Litigation) relatively quickly compared to other pharmaceutical injury cases. This is due to the strong scientific evidence, federal coordination, and increasing interest from attorneys nationwide.

This litigation will involve both an MDL class action and individual state court actions. Whether you’re following the Depo shot lawsuit generally or are concerned about how it might affect you personally, we can help you stay informed. Early bellwether trials, rulings on motions such as Pfizer’s preemption defense, and deadlines for proving use/injury will all play a role in shaping these cases and influencing potential Depo-Provera settlement values.

News Roundup

March 18, 2025

The Depo-Provera brain tumor litigation is rapidly expanding, with 3,467 cases involving 3,790 plaintiffs currently pending in the federal multidistrict litigation. This information comes from a new case management order issued after the court’s March 6 conference. New filings are being submitted at a rate of approximately 650 per month, indicating that the litigation is still growing. While a high number of plaintiffs could raise concerns about the defendant’s ability to pay, in this case, the defendant is Pfizer.

The litigation is now entering a crucial phase focused on the scientific evidence linking Depo-Provera to meningioma brain tumors. Expert depositions on general causation are underway and scheduled through March 20, with challenges to those experts expected later this spring. Any motions seeking to exclude expert testimony under the Daubert standard will be fully briefed by May 29.

The court is also reviewing Pfizer’s summary judgment motion, which argues federal preemption, a defense the company hopes will limit or eliminate some claims. That motion is now fully briefed and awaiting a decision from the court.

Over 94% of complaints have been submitted without deficiencies, and only a small number of cases have required court intervention over missing documentation.

In addition to the federal MDL, state court litigation is also growing, with hundreds of additional plaintiffs pursuing claims in Delaware, New York, California, and other jurisdictions.

The next case management conference in the MDL is scheduled for April 17, 2026, as the court continues preparing the litigation for the eventual selection of early test cases.

New Depo Provera Lawsuit

March 16, 2025

In a new lawsuit, a woman from San Antonio, Texas, alleges that she used Depo-Provera for birth control for approximately 14 years, starting in 2008 at age 38 and continuing through 2022. She received repeated injections over that period, including both branded and authorized generic versions.

The lawsuit highlights the progression of her symptoms over time. It states that while she was still receiving injections, she began experiencing “painful and disturbing” symptoms, including headaches, dizziness, vertigo, insomnia, and irritability. In 2022, she underwent an MRI and was diagnosed with a meningioma at age 51.

She alleges that she underwent surgery for the intracranial meningioma and has continued to suffer complications. The suit claims she has been permanently and severely injured, with ongoing mental and physical pain, emotional distress, and economic losses, including past and future medical expenses.

The lawsuit states that despite consulting medical providers and conducting a diligent investigation, she could not reasonably have discovered the relationship between her injuries and the drug until October 2024.

50% Increase in New Lawsuits

March 4, 2025

The growth in this litigation has been significant. There are now 3,099 filed lawsuits, almost 50% more than last month.

GET MORE Depo Provera Lawsuit Updates and News 👈

Why 150 Milligrams?

February 25, 2025

Depo-Provera is administered as a 150 mg intramuscular injection, which delivers a high dose of synthetic progestin into the bloodstream for months. However, it raises the question of whether such a high dose was ever truly necessary. Lower-dose versions, like Depo-SubQ Provera 104, achieve the same contraceptive effect with significantly less drug. So, why has Pfizer maintained the higher 150 mg formula for so long?

Plaintiffs in the litigation argue that this unnecessarily high dosage may have increased the risk of brain tumors, specifically intracranial meningiomas. Pretrial discovery will need to investigate whether Pfizer ever re-evaluated this dose in light of newer scientific findings or whether the 150 mg dose persisted due to convenience, inertia, or profit motives. If safer alternatives were available and Pfizer chose to ignore them, jurors will be asked to consider whether that decision put women at unnecessary risk.

The sustained release of the 150 mg dose is particularly concerning. Unlike a daily birth control pill, Depo-Provera acts more like setting a hormonal thermostat to high and then sealing it shut for three months. Once injected, medroxyprogesterone acetate floods the system and maintains sustained levels that only gradually decrease over time.

Given that lower doses can effectively prevent pregnancy, the question arises as to why the higher dose has been used. This question is even more critical considering that meningiomas are hormone-sensitive tumors that express progesterone receptors and can grow in response to progestin exposure. The litigation will focus on whether Pfizer knowingly maintained the high dose long after scientific evidence suggested that a lower dose might have been sufficient.

Delaware Depo Provera Docket Growing

February 21, 2026

Lawsuits continue to be filed outside of the MDL. In one new meningioma lawsuit filed in Delaware state court, a woman from Brownsville, Tennessee, alleges that she developed an intracranial meningioma after using Depo-Provera.

According to the complaint, the plaintiff was prescribed and administered the Depo shot from approximately 2019 to 2021. On July 1, 2022, she was diagnosed with a meningioma.

She claims that as a result of the tumor and subsequent treatment, she has suffered significant bodily injury, pain and suffering, mental anguish, disfigurement, loss of earnings and earning capacity, and substantial past and future medical expenses.

Keeping Documents Under Seal

February 20, 2026

The plaintiffs and Pfizer have jointly submitted a consent motion asking the court for permission to file certain materials under seal.

The motion relates to plaintiffs’ supplemental brief opposing Pfizer’s motion for summary judgment based on federal preemption. Plaintiffs seek to file an unredacted version of that brief, along with an internal October 15, 2025 email concerning Depo-Provera labeling, under seal because the documents contain confidential business information. Pfizer consents to the request.

While the parties agree that the materials should not be publicly accessible, the court must still determine whether “good cause” exists to seal them.

Updated Case Count

February 17, 2026

There are now more than 2,100 Depo Provera suits in the MDL.

Conference Postponed

February 9, 2026

Due to a scheduling conflict, Judge Rodgers has cancelled the February 20, 2026, Case Management Conference. The Eleventh CMC will now take place on March 6, 2026. As a result of this change, the March 13, 2026 CMC has also been cancelled.

The parties must submit a Joint Agenda Letter no later than 12:00 p.m. CT on Monday, March 2, 2026, to the MDL court, as well as to the courts in New York, Delaware, and California, where significant Depo Provera dockets exist.

Preemption Ruling Delayed with New Depo Provera Warning

January 30, 2026

On January 27, 2026, Judge M. Casey Rodgers entered Pretrial Order No. 30 in the Depo-Provera MDL. The court clarified that its upcoming rulings on federal preemption and expert causation will apply across the entire MDL, not just the five pilot cases. This means that the next steps will have significant implications for all cases.

The order confirms that if Pfizer wins on preemption, the MDL essentially ends. However, if Pfizer loses, the case moves directly into Rule 702 hearings on general causation, already scheduled for late May 2026.

The timing of this order is particularly noteworthy. After oral argument on preemption, the FDA approved Pfizer’s request to add a meningioma warning to Depo-Provera’s U.S. label in December 2025. This development challenged Pfizer’s preemption argument, and Judge Rodgers immediately ordered supplemental briefing to address it. Plaintiffs have until February 20 to respond, and individual plaintiffs are expressly allowed to file their own briefs if they have materially different arguments.

Cases Total 1,775

January 6, 2026

The Depo-Provera brain cancer MDL has 1,752 pending cases, with 1,775 total cases as of January 2026.

While the number of state court cases is unknown, New York and Delaware have the most. However, the core of this litigation is the MDL.

FDA Approves New Warning Label

December 18, 2025

The FDA has formally approved the addition of new language to the warning label for Depo-Provera regarding the risk of meningioma brain tumors. The new label will now contain the following language:

“Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma. Discontinue Depo-Provera CI if a meningioma is diagnosed.”

Depo-Provera Litigation Updates

This new language was added and approved at Pfizer’s request, potentially to limit future liability.

Significant Increase in New Cases Added to MDL in November

December 9, 2025

The Depo-Provera brain cancer MDL is gaining considerable momentum. During November, 245 new cases were added, bringing the total number of pending cases to 1,470.

Only Three New Cases Added to MDL

November 4, 2025

In October, only three new cases were added to the Depo-Provera brain tumor MDL, increasing the total pending case count to 1,225.

Preemption Hearing

September 30, 2025

Yesterday’s hearing was crucial in the Depo-Provera litigation. Judge Rodgers heard arguments regarding Pfizer’s motion for summary judgment. Pfizer argued that federal preemption prevents failure-to-warn claims, while plaintiffs’ counsel contended that Pfizer withheld vital evidence from the FDA, weakening any potential defense.

Judge Rodgers provided little indication of her final decision. She posed pointed questions to both sides but gave no clear signals from the bench. Nevertheless, the hearing was productive, and plaintiffs’ attorneys left feeling optimistic, believing that Pfizer’s preemption argument is unlikely to end the federal litigation.

Additionally, there was a 90-minute case management conference yesterday with no major developments.

The Big Hearing Is Monday

September 26, 2025

On Monday, Judge Rodgers will dedicate the afternoon to the most critical issue in the Depo-Provera litigation: whether the plaintiffs’ failure-to-warn claims can proceed or if federal preemption blocks them. The hearing precedes Pfizer’s motion for summary judgment, which asserts that the FDA’s rejection of proposed label changes shields the company from liability.

Each side will have 75 minutes to present their arguments. Pfizer will argue that federal law prevented them from adding brain tumor warnings without FDA approval. In contrast, plaintiffs will argue that the company misrepresented or withheld critical evidence in its label submission, making the preemption defense invalid. Judge Rodgers has allocated 2.5 hours after the morning case management conference for these arguments, highlighting the pivotal nature of this ruling.

Monday’s hearing will determine the course for thousands of women awaiting their day in court. While Judge Rodgers is unlikely to rule immediately, the hearing may offer valuable insights into her thinking. Her questions and tone during the arguments could provide both sides with their first real indication of her view on Pfizer’s preemption defense.

Ultimately, if the motion is denied, as Nguyen Injury Lawyer hopes and expects, the litigation will proceed with five pilot bellwether cases. If it is granted, the plaintiffs’ strongest argument would never reach a jury in federal court, assuming an appeal is unsuccessful.

New Cleveland Clinic Study

September 3, 2025

The new Cleveland Clinic study in JAMA Neurology has altered the landscape of the Depo-Provera litigation. Researchers examined over ten million women across sixty-eight health care systems and discovered that long-term users of the birth control shot, particularly those who started after age thirty-one or used it for more than four years, face a significantly higher risk of intracranial meningioma. The relative risk was 2.43 compared to women who never used the drug, while every other form of contraception studied showed no measurable danger. While not as strong as the Roland study, it is still sufficient for Daubert standards.

These numbers translate to real-world consequences. Approximately one additional tumor is expected for every 1,100 women exposed. Given that the product has been injected into tens of millions of women over decades, this “small” risk translates to thousands of preventable tumors, often requiring surgery and lifelong monitoring. No one wants a brain tumor.

Regarding litigation, the study eliminates the defense’s argument that there was no U.S. population data. That defense is no longer valid. Plaintiffs now have peer-reviewed, large-scale evidence demonstrating that the injectable form of medroxyprogesterone carries risks that no other contraceptive does. The central question becomes why Pfizer and others failed to warn when safer alternatives were readily available. This type of study influences how judges and juries view the science and provides plaintiffs with a stronger foundation to move forward beyond the Roland study.

Preemption Motion

September 2, 2025

Pfizer is aggressively pursuing a preemption victory in the Depo-Provera MDL. A new motion claims the FDA prevented it from adding a meningioma warning after a formal request in 2024. The company states that it submitted a detailed application with data from recent epidemiological studies, adverse event reports, and proposed warning language. Nine months later, the FDA issued a complete response letter denying the request, stating that the evidence did not support a label change. Now, Pfizer argues that this federal rejection bars state-law failure-to-warn claims.

This move aims to end the litigation before plaintiffs reach discovery. However, it overlooks the fundamental issue: Pfizer suppressed data linking synthetic progestins to meningiomas for decades. Plaintiffs argue that the company could have acted much earlier than its belated 2024 submission. Pfizer’s tactic reframes the case as one of regulatory constraint rather than long-term corporate inaction.

Moreover, Nguyen Injury Lawyer will respond that Pfizer still has available options. The CBE process could have been used to strengthen the warning unilaterally, especially given that studies like Roland showed a fivefold increased risk. More importantly, the FDA never prohibited a risk-based warning with real clinical utility. Pfizer seeks to portray its rejected request as the final word, but it was merely a minimal effort.

If the court accepts Pfizer’s theory, it could eliminate both the warning and design defect claims in one action. However, this would ignore the broader pattern of delay and minimization that has defined the company’s handling of Depo-Provera’s risks. This case is not about a single rejected label change; it is about years of missed opportunities to protect patients. If you or a loved one has been affected, contact Nguyen Injury Lawyer at XXX-XXX-XXXX for a consultation.

Waiting on the Sidelines in the MDL

August 22, 2025

Judge M. Casey Rodgers issued an order directing lead plaintiffs’ firms to disclose the number of unfiled cases they are holding. She clarified that if law firms flood the docket with cases after a ruling on preemption, their leadership positions may be at risk.

Why does the MDL judge care? Rodgers’ concern is straightforward: warehousing cases makes it harder for the court to determine the true scope of the litigation, manage scheduling, and prepare for settlement or trial. This is what occurred in the AFFF litigation, where defendants panicked about the number of unfiled claims, and the judge sided with them.

This tension is not new. In other mass torts, plaintiffs’ lawyers have learned that filing too many cases too early can backfire. Judges and defendants scrutinize inventories, demand science up front, and use procedural tactics like preemption to undermine claims. In Zantac, plaintiffs’ firms diligently loaded the MDL registry with thousands of claims, confident that the science and the courts would eventually vindicate them. Then, the judge issued her sweeping Daubert and preemption rulings. In one fell swoop, the registry became a sinkhole for thousands of claims that had never been seen in a courtroom. Lawyers who thought they were acting responsibly by filing early watched as their cases and their clients’ hopes vanished.

So, yes, Judge Rodgers’ suspicion is correct, but the strategy makes sense. Plaintiffs’ Depo-Provera attorneys are not “warehousing” claims for fun. Our job is to protect our clients. Nguyen Injury Lawyer is dedicated to advocating for those harmed by dangerous drugs.

The ideal solution is a claims registry. Cases are logged so the court has full visibility, and if the judge were to grant preemption (an unlikely outcome on these facts), those claims would simply be dismissed without prejudice. This approach provides the court with clarity, protects plaintiffs from unnecessary risk, and ensures no one is penalized for filing responsibly. If you have questions about your case, contact Nguyen Injury Lawyer through our contact page or by calling XXX-XXX-XXXX.

Attorneys’ Fees Dispute

August 16, 2025

A firm has filed a motion objecting to the scope of the court’s Amended Common Benefit Order No. 1. The order defines any lawyer with a single case in the MDL as “Participating Counsel” and claims the power to withhold fees not only from cases in the MDL but also from unrelated cases in state court or not yet filed. The motion argues that this exceeds the court’s authority because the plaintiffs in those other cases have not benefited from any MDL settlement and have not agreed to contribute.

At the center of the dispute is the concept of a common benefit fund. These funds are used to fairly compensate lawyers who perform work that helps all plaintiffs in mass tort litigation. When a settlement is reached, courts may allow a percentage of each recovery to be set aside for the lawyers who led the charge. But that kind of holdback is only allowed when a settlement creates a common fund or when the attorneys agree in advance to contribute. Without one of those two triggers, the court has no power to take a portion of fees from clients who have not participated.

Fights like this are common in large MDLs. We just saw one in the hair relaxer litigation. They reflect the constant tension between centralized efficiency and the individual autonomy of plaintiffs and their lawyers. Courts want to prevent free riding on leadership counsel’s work, but it gets tricky when they impose financial obligations on cases that are outside their jurisdiction or that have not consented.

More Depo Shot Lawsuits in Delaware

August 12, 2025

In a new lawsuit filed yesterday in the Superior Court of the State of Delaware, 100 plaintiffs joined the growing number of Depo-Provera cases being filed outside the federal MDL class action lawsuit that serves as the epicenter of coordinated nationwide proceedings.

While the MDL consolidates federal claims for efficiency, plaintiffs are increasingly turning to Delaware state court (where Pfizer and its subsidiaries are incorporated) and other states to pursue parallel actions that can move on a separate track and offer strategic advantages. For expert legal guidance, contact Nguyen Injury Lawyer at XXX-XXX-XXXX.

Philadelphia Depo-Provera Mass Tort Stalls Out

June 16, 2025

It appeared that a coordinated Depo-Provera mass tort was developing in the Philadelphia Court of Common Pleas, as Nguyen Injury Lawyer predicted months ago. However, after a judge severed nearly all of the 100 plaintiffs from a consolidated case and allowed them to refile individually, no new filings were made. Pfizer withdrew its petition for coordination, and only one case remains. For now, Philadelphia is no longer a focal point for this litigation.

While the Philadelphia docket has become quiet, more than 400 cases remain active in the federal MDL in the Northern District of Florida, with additional lawsuits filed in state courts nationwide. This is where the litigation momentum lies, at least for now.

Consolidated Litigation in Pennsylvania

June 8, 2025

Nguyen Injury Lawyer has long anticipated that this litigation would involve active state court dockets in addition to the federal MDL, and that is precisely what is happening. Depo-Provera meningioma lawsuits are now proceeding in multiple state courts across the country, creating a parallel track of litigation that will likely remain active for the foreseeable future.

In California, six cases are pending, and defendants have already filed a petition seeking coordination. The Judicial Council has asked the Presiding Judge in Alameda County to assign a coordinating judge and recommend a venue for the coordinated proceedings.

State Court Litigation Developments

New York is rapidly becoming the leading state-level jurisdiction, with 60 Depo-Provera cases currently active. The possibility of a coordinated proceeding in New York is high. The Litigation Coordinating Panel has put 58 of these cases on hold, with a deadline of June 18 for any objections to the joint coordination petition. Given that the plaintiffs involved have already agreed to the request, opposition is not anticipated. Both plaintiffs and defendants have agreed to utilize BrownGreer Centrality for case management and service, indicating a serious and well-organized effort to manage the docket efficiently.

In other state courts, there are three cases in Pennsylvania (including one large complaint involving 100 plaintiffs) and individual cases pending in Illinois, New Mexico, and Delaware. It is important to note that the Illinois case count excludes the Daniels case, which has already been moved to federal court.

Defendants and plaintiffs are showing cooperative efforts, especially in California and New York, to prevent redundant discovery and motion practices. These state court proceedings are likely to continue to play a key role in determining the overall direction of this litigation. If you believe you have a claim, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com/contact.

Projected Number of Depo-Provera Lawsuits

May 13, 2025

Each year, approximately 2 to 3 million prescriptions for Depo-Provera are filled in the United States. The baseline incidence of meningioma in the general population is about 9.5 cases per 100,000 people annually. This means that, based solely on population averages, there would be approximately 190 to 285 cases of meningioma each year among Depo-Provera users.

However, when considering a 5.5x increased risk due to Depo-Provera, the estimated number of annual meningioma cases among users rises to between 1,045 and 1,568.

It is important to remember that not every patient who develops meningioma will decide to pursue legal action. Various factors, such as the statute of limitations, awareness of the connection, evidence of causation, and the severity of the injury, will influence whether a claim is filed. Historically, in mass torts, only 5% to 20% of potentially injured individuals file lawsuits. If you believe you have a claim, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com/contact.

Evidence Required to Participate in Depo Shot MDL

May 12, 2025

Judge M. Casey Rodgers recently issued Pretrial Order No. 22, which details how deficiencies in plaintiffs’ Proof of Use and Injury submissions will be identified and handled. All plaintiffs involved in the Depo-Provera MDL must complete a Use/Injury Questionnaire and submit all supporting documentation through the BrownGreer MDL Centrality system.

The order emphasizes that plaintiffs must provide clear evidence that they were administered a qualifying Depo-Provera product and that they received a diagnosis of a qualifying meningioma.

What does this requirement mean, and what does it not mean? It is important to remember that the full range of potential injuries that could be linked to long-term Depo-Provera use is not yet fully known. The science is still evolving, and meningioma is simply the injury that currently has the strongest research support – as well as the most serious injuries – connecting it to the drug. The MDL is not trying to resolve every possible injury theory all at once. Instead, the court has made it clear that the litigation will focus specifically on meningioma claims, at least for the purposes of these coordinated proceedings in federal court.

This does not necessarily mean that other potential injuries could never be pursued in separate litigation if stronger evidence emerges in the future. It simply reflects the practical way that MDLs typically function. Courts usually narrow the scope of a case to the injury with the most developed scientific support. This allows discovery, expert testimony, and bellwether trials to proceed in an organized manner. In this MDL, Judge Rodgers has determined that meningioma will be the central injury claim moving forward, and plaintiffs must be able to document both Depo-Provera use and a meningioma diagnosis to participate in the litigation. If you believe you have a claim, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com/contact.

Meningioma Study Backs Up Roland Study

May 6, 2025

Researchers at the University of British Columbia have released a new safety study that is providing additional momentum for plaintiffs in the Depo-Provera brain tumor litigation.

In a nested case-control study, researchers led by Connor Frey and Mahyar Etminan analyzed data from over 319,000 contraceptive users to compare the risk of intracranial meningioma in women who used Depo-Provera versus women who used a popular combination oral contraceptive (ethinylestradiol-levonorgestrel, or EE-LNG).

The results were concerning. After adjusting for disease latency, obesity, prior radiation, and previous contraceptive use, the study found that women who used Depo-Provera for more than one year had a 3.55-fold increased risk of developing a meningioma. As we have been saying, the risk remained elevated after longer use. These findings translate to an estimated number needed to harm (NNH) of just 1,111, meaning that one in every 1,111 women using Depo-Provera for three years could develop a brain tumor. The authors emphasized the biological plausibility of this link, citing the role of progesterone receptors in tumor cell proliferation, and criticized the FDA for not including meningioma risk on the U.S. label, unlike European regulators. If you believe you have a claim, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com/contact.

The Depo-Provera MDL was initiated because of the Roland study, which we discuss at length below. That study found a 5.6-fold increased risk of meningioma with MPA use. However, that study had limitations. It was based on only eight exposed cases, lacked an active comparator, and did not adjust for the long latency period associated with tumor development, which left it open to defense attacks claiming reverse causation.

The new Frey study corrects all of those flaws. It uses a much larger sample size (212 cases and 848 controls), compares Depo-Provera to another active hormonal contraceptive (EE-LNG), and introduces lag periods of up to four years to account for disease latency. These methodological improvements make Frey’s findings far more robust and harder for defendants to undermine during Daubert challenges or in future bellwether trials. In short, this study confirms what Roland suggested and strengthens the case for warning label failures.

March 31, 2025: Proof of Product Use

Providing evidence of Depo Provera use will be a central component of this litigation. Our attorneys at Nguyen Injury Lawyer have proposed a uniform, court-authorized process for gathering proof-of-use evidence in the MDL.

Plaintiffs are now required to complete a “Plaintiff Proof of Use/Injury Questionnaire” within 120 days of March 14, 2025 (or within 120 days of filing for newly added cases). To meet this requirement, this order compels third parties—including pharmacies, clinics, hospitals, insurance companies, and military medical providers—to provide records confirming whether a plaintiff was injected with Depo-Provera or its generic equivalent (DMPA), even when traditional medical records may no longer be available. If you believe you have a claim, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com/contact.

Many of the women in this litigation received Depo-Provera injections years ago, and in many cases, individual medical records have been lost, destroyed, or never identified the specific manufacturer of the DMPA injection. However, institutions often retain distribution records like purchase orders, shipping logs, or insurance payment data that can show whether a facility used Pfizer’s Depo-Provera or a generic version during a specific time period.

The order authorizes plaintiffs to use a court-approved HIPAA and HITECH-compliant release form, along with a medical provider identification form, to request those records. If providers refuse to cooperate voluntarily, counsel may serve them with a subpoena incorporating the same authorization without having to jump through any additional hurdles. The judge under this order would require third-party entities to comply with these subpoenas or releases, and they cannot impose facility-specific red tape, such as requiring their own forms, original signatures, or unreasonable processing fees that slow down the process.

January 28, 2025: Is It All About the Money?

We discuss anticipated Depo-Provera settlement amounts in detail below. Some people ask whether these cases are solely about the money victims may receive. The answer is both yes and no. These lawsuits serve a larger purpose: they help protect women by holding pharmaceutical companies accountable for their actions. If you believe you have a claim, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com/contact.

However, it is important to remember that in civil cases like these, financial compensation is the only form of justice available to victims. The time for sympathy or apologies from Pfizer and the other defendants has long passed. From our perspective at Nguyen Injury Lawyer, our mission is clear: to maximize the settlement compensation our clients deserve for their suffering. So, yes, in some ways, it is about the money—but it is also about ensuring justice.

December 7, 2024: New Lawsuit in Pennsylvania State Court

As we have said, we expect a substantial Depo Provera docket in Philadelphia. On Thursday, a new Depo shot lawsuit was filed in the Court of Common Pleas for Philadelphia County. A Philadelphia resident alleges that prolonged use of the injectable contraceptive Depo-Provera caused her to develop a debilitating meningioma. The plaintiff, who began these injections as a teenager, claims that the manufacturers, including Pfizer and several associated companies, failed to adequately warn of the risks linked to the synthetic hormone medroxyprogesterone acetate, the active ingredient in Depo-Provera. If you believe you have a claim, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com/contact.

The plaintiff, who underwent multiple brain surgeries and suffers from ongoing physical and cognitive impairments, seeks compensatory and punitive damages for her injuries.

October 31, 2024 – European Warning

As we have discussed, Pfizer has implemented label changes for Depo-Provera in the European Union and the United Kingdom, with potential updates in other regions.

The added cautionary language under “Special warnings and precautions for use” in the EU label states:

“Meningioma: Meningiomas have been reported following long-term administration of progestogens, including medroxyprogesterone acetate. Depo-Provera should be discontinued if a meningioma is diagnosed. Caution is advised when recommending Depo-Provera to patients with a history of meningioma.”

Plaintiffs’ attorneys will, with good reason, continue to press Pfizer on this issue. The optics of providing a warning there but not here are simply unacceptable. However, the reality is that this wording is vague and does not fully address the severity of the risk. The label merely suggests “caution” in prescribing Depo-Provera to patients with a history of meningioma, without any strong warnings about the drug’s potential to cause these tumors, even in those without such a history. It advises discontinuation only after diagnosis, disregarding the likelihood of irreversible harm by that stage. If you believe you have a claim, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com/contact.

Pfizer needs a stronger, more explicit warning on this product everywhere that provides a real warning of the risk of meningioma. If it chooses to give this watered-down warning in the U.S.—and there will be a warning eventually—our Depo Provera lawyers will correctly view it as no warning at all.

October 8, 2024: Depo Provera Lawsuit Statute of Limitations

Many women contacting Nguyen Injury Lawyer are concerned about the deadline for filing a Depo-Provera lawsuit. Lawyers are always mindful of the statute of limitations. But there should not be many statute of limitations issues in this case for women acting now. There are two primary reasons why the statute of limitations should not be a significant concern. If you believe you have a claim, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com/contact.

The first reason is the discovery rule, which every state has in varying forms. The discovery rule is a legal principle that delays the start of the statute of limitations until a plaintiff knows, or reasonably should know, about both the injury and its connection to the defendant’s conduct.

Legal Arguments in Depo-Provera Meningioma Lawsuits

In Depo-Provera meningioma lawsuits, it’s important to understand why the legal clock may not have started ticking when a woman was first diagnosed. Women who developed brain tumors may not have had reason to suspect a connection to Depo-Provera until recent scientific studies highlighted this link. Before this, the association between Depo-Provera and brain tumors was not widely recognized by the public or the medical community. Therefore, it would have been unreasonable for plaintiffs to connect their diagnosis to the drug years earlier.

Another key legal concept is fraudulent concealment. Nguyen Injury Lawyer can argue that the manufacturers and marketers of Depo-Provera intentionally hid the known risks associated with its long-term use.

Depo-Provera Lawsuits and the Philadelphia Court System

It is anticipated that many Depo-Provera lawsuits from across the country will be filed in the Court of Common Pleas in Philadelphia, Pennsylvania. You might wonder why a case from Texas, New York, or California would be filed in Pennsylvania state court.

The Philadelphia Court of Common Pleas is well-regarded for its experienced judges who handle complex mass tort and product liability cases. This makes it an appealing venue for plaintiffs’ attorneys. The court’s Complex Litigation Center (CLC) is known for its efficient management of large caseloads and its history of significant verdicts and settlements for plaintiffs.

One reason plaintiffs from other states can file in Pennsylvania is that one of the defendants in the litigation, Viatris Inc., is headquartered in Canonsburg, Pennsylvania. This allows plaintiffs to sue all defendants in state court in Pennsylvania.

Pennsylvania’s procedural laws offer some flexibility in consolidating cases, which can streamline litigation and reduce costs for plaintiffs. Additionally, the state’s rules on expert testimony are often considered more favorable to plaintiffs, making it easier to present scientific evidence. While this is less of a concern in this litigation, it can be a factor.

Perhaps most importantly, Philadelphia juries are often seen as particularly empathetic and fair to individuals harmed by corporate negligence. They are known for holding large companies accountable and carefully considering the impact on victims. This makes the city an attractive venue for plaintiffs seeking justice against powerful corporate defendants.

Our lawyers have observed how this reputation can significantly influence litigation and settlement discussions. Drug companies like Pfizer may view the prospect of a jury trial in Philadelphia as a compelling reason to offer fair Depo-Provera settlement offers.

Ultimately, Nguyen Injury Lawyer expects to see a Depo-Provera federal class action-type lawsuit (an MDL) and smaller class actions in various state courts around the country.

Why an MDL is More Likely Than a Traditional Class Action

It is more likely that this litigation will be consolidated in an MDL rather than a traditional Depo-Provera class action lawsuit. Why? Because an MDL is often the better path for women to receive compensation.

A Depo-Provera class action lawsuit would combine all plaintiffs into a single case, with one trial or settlement covering everyone. Any compensation would be divided equally among participants, regardless of individual circumstances. This isn’t ideal because the injuries women have suffered vary significantly.

An MDL works differently, allowing each plaintiff to maintain their individual case. This means their injuries and damages are evaluated on a case-by-case basis. In an MDL, pretrial proceedings are consolidated for efficiency, but the cases remain separate. Individual cases can still proceed to trial if a global settlement isn’t reached. This structure is often more suitable for cases like this.

In addition to federal multidistrict litigation, state MDLs can also be created when enough cases are filed within a single state court system. State MDLs follow a similar process by grouping related cases under one judge for pretrial proceedings, but they remain within the jurisdiction of state courts rather than federal ones. This could happen in the Depo-Provera litigation in states like Ohio, Pennsylvania, and New York, where some Depo-Provera corporate defendants reside, making them amenable to suit there. In large pharmaceutical litigations like Depo-Provera, parallel MDLs at both the state and federal levels are common, each working toward a global resolution or individual trial outcomes.

Frequently Asked Questions About Depo-Provera Lawsuits

Is Depo-Provera the Next Mass Tort to Explode in 2026?

Yes, it is likely. The scientific evidence linking Depo-Provera to meningioma is strong compared to other pharmaceutical litigation. A BMJ study found that women using the birth control shot for over a year were 5.6 times more likely to develop a meningioma. Additional studies are emerging that support the concerns raised in that study.

A 5.6 times increased risk is a significant concern. In mass tort cases, such clear, statistically significant evidence linking a drug to a serious condition makes it easier for plaintiffs’ lawyers to prove their claims and puts pressure on the defendants.

Although things have slowed down a bit as 2026 progresses, Nguyen Injury Lawyer is still seeing many new cases. With the Depo-Provera class action lawsuit (actually an MDL) now established with a judge who will move things forward, this litigation is expected to proceed quickly. Plaintiffs’ lawyers are currently focusing more energy on the Depo-Provera litigation than on any other mass tort in the country.

How Much Money Could a Depo-Provera Lawsuit Be Worth?

It is still early in the litigation process, making it difficult to predict Depo-Provera settlement payouts with certainty. However, based on our current understanding, we can provide our best assessment of how things might unfold if the litigation is successful.

Our attorneys estimate that individual settlements could range from $275,000 to over $1.5 million. This is a broad range, but it reflects the current uncertainty. The most severe cases, involving multiple surgeries, permanent disabilities, or life-altering complications, could be worth even more. These are serious injuries, including brain surgery, long-term cognitive issues, and a lifetime of medical monitoring.

While Pfizer has the resources to fight, the scale and seriousness of these claims place this litigation in high-value mass tort territory. Ultimately, we anticipate that the key question will be not whether these cases will settle, but when and for how much. However, there is still work to be done.

More information about how our lawyers view potential Depo-Provera lawsuit settlement payouts is provided below.

How Do We Know Pfizer Knew About the Brain Tumor Risk?

This isn’t a new issue. Studies linking Depo-Provera to meningioma date back to 1983, when researchers discovered that synthetic hormones could stimulate progesterone receptors in these tumors. This was a significant warning sign that was not adequately investigated.

European regulators recognized the warning signs and required Pfizer to add a meningioma warning. Canada followed suit. However, in the United States, no such warning was added.

Pfizer was aware of the risks. The science was available. However, instead of updating the warning label, they kept the information quiet and continued to profit. As history has shown, profits often take precedence over public safety.

What’s Happening in Court? Where Are These Cases Filed?

The Judicial Panel on Multidistrict Litigation (JPML) has consolidated all federal court lawsuits into an MDL in the Northern District of Florida under Judge Casey Rodgers. As of February 2026, over 2,000 lawsuits have been filed in the MDL, but plaintiffs’ lawyers report holding nearly 10,000 unfiled claims. We can expect thousands more cases to follow. In addition, Philadelphia state courts may see a significant number of claims, and we are also seeing more lawsuits in Delaware and California.

Who Qualifies for a Depo-Provera Lawsuit?

If you received at least two injections of Depo-Provera and were later diagnosed with a meningioma brain tumor, you may have a strong legal claim. Nguyen Injury Lawyer is currently investigating cases where this long-acting birth control shot may be linked to the development of meningiomas — tumors that grow in the lining of the brain and can cause severe neurological issues.

The strongest cases involve women who used Depo-Provera for five years or more. However, even women with shorter-term use may be eligible, especially if the tumor required surgery or caused symptoms like vision problems, seizures, or memory loss.

Meningiomas can be slow-growing but dangerous. Many women were never warned about the risk, and the connection between Depo-Provera and these brain tumors is only now becoming clear.

How Many Depo-Provera Lawsuits Are Expected?

Current estimates suggest there could be between 16,000 and 18,000 cases involving women diagnosed with progesterone receptor-positive meningiomas. Plaintiffs’ lawyers indicate they have at least 10,000 more cases that may be filed.

When considering the number of women who remain undiagnosed, the possibility of misattributed symptoms, and the many patients who have yet to connect their diagnosis to Depo-Provera, the true number of affected women may be significantly higher.

While not all of these women will pursue legal action, the scale of the harm is becoming increasingly evident. Nguyen Injury Lawyer is witnessing this firsthand. The high volume of calls our law firm receives from women nationwide paints a picture of a widespread public health issue. Many of these women are just now learning about the potential connection between Depo-Provera and their tumors after years of unexplained symptoms.

The combination of high exposure numbers, the seriousness of the injury, and the lack of adequate warnings from the manufacturer suggests this litigation will grow quickly. Our lawyers anticipate that this litigation will grow rapidly and substantially as more women come forward, medical providers become increasingly aware of the link, and courts begin to address the claims. This is shaping up to be a significant fight for accountability and a chance for thousands of women to seek justice and compensation.

How Can I File a Depo-Provera Lawsuit?

If you or a loved one developed a meningioma brain tumor after using Depo-Provera, you may be entitled to significant financial compensation. We make the process as simple as possible for you. Call XXX-XXX-XXXX or contact us online today for a free case evaluation.

What is Depo-Provera?

Depo-Provera is the brand name for medroxyprogesterone acetate. Often called the birth control shot, it is an injectable form of contraception for women. It is administered by injection (in the arm or butt) every three months and provides a highly effective, long-lasting option without the need for daily attention, as long as it is taken on schedule.

Pfizer has profited greatly from Depo-Provera. A recent National Health Statistics Report from December 2023 indicates that nearly 24.5% of all sexually experienced women in the United States used Depo-Provera at some point between 2015 and 2019.

Depo-Provera’s journey to approval as a contraceptive involved decades of regulatory challenges and controversy. Initially developed by Upjohn (now part of Pfizer) in the 1950s, Depo-Provera—depot medroxyprogesterone acetate (DMPA)—was intended as an injectable treatment for endometrial and renal cancers.

Depo-Provera’s History and Controversies

Depo-Provera’s contraceptive action stems from high doses of progestin that halt ovulation. Upjohn initially sought FDA approval in 1967, but the application was denied due to cancer concerns, an early indication that foreshadowed today’s brain tumor lawsuits. Subsequent applications in 1978 and 1983 met the same fate due to similar safety issues.

Prior to U.S. approval, Upjohn successfully marketed Depo-Provera internationally, including in France as early as 1969. In the U.S., the drug sparked considerable controversy as data emerged regarding its long-term effects. Following further studies and increased global acceptance, the FDA approved Depo-Provera as a contraceptive in 1992.

Controversy persisted, particularly concerning potential links to bone density loss and heightened risks of certain cancers and neurological conditions like meningiomas. In 1995, Upjohn merged with Pharmacia, a Swedish company. Pfizer then acquired Pharmacia & Upjohn in 2002, assuming the regulatory responsibilities and liabilities associated with Depo-Provera.

While generic versions of Depo-Provera have been available for years, many are still manufactured by Pfizer and sold as generics by other companies.

Study Links Depo-Provera to Brain Tumors

A significant scientific study released in March 2024 established a clear connection between Depo-Provera use and the development of meningiomas, a specific type of brain tumor. The findings were published in the respected British Medical Journal.

The study examined the relationship between progestogens (hormone medications) and meningioma risk, analyzing data from the French National Health Data System, which included women who underwent meningioma surgery in France.

The study involved 108,366 women, including 18,061 who had undergone surgery for meningioma, making it a large-scale investigation.

Key findings included:

• Long-term use (over one year) of specific progestogens—medrogestone, medroxyprogesterone acetate, and promegestone—was associated with an increased risk of meningiomas.
• No increased risk was found for other hormonal treatments like progesterone, dydrogesterone, and certain hormonal intrauterine devices (IUDs).

Our attorneys at Nguyen Injury Lawyer carefully evaluate studies in drug litigation, paying close attention to the odds ratio, which indicates the likelihood of developing a condition in users versus non-users. For example, an odds ratio of 2 suggests users are twice as likely to develop the condition.

In this study, medroxyprogesterone acetate (MPA), or Depo-Provera, showed a striking odds ratio of 5.55. Nine cases out of 18,061 (0.05%) were exposed to MPA, compared to 11 controls out of 90,305 (0.01%). Such a strong odds ratio is rare in tort claims.

Previous Studies Put Pfizer on Notice of a Problem

This wasn’t the first study to suggest a meningioma risk. In 1983, a study in the European Journal of Cancer & Clinical Oncology identified a high concentration of progesterone receptors in human meningioma cells. The research focused on the relationship between progesterone and meningioma growth by examining the concentration of hormone receptors, specifically progesterone receptors, in meningioma cells. The research demonstrated that meningioma cells possess a greater density of progesterone receptors compared to estrogen receptors.

The study’s key finding was that meningioma cells contained a higher density of progesterone receptors than estrogen receptors, indicating that meningiomas, typically slow-growing brain tumors, could be influenced by progesterone levels. This provided a biological explanation for how hormone-based drugs like Depo-Provera (containing synthetic progesterone) might accelerate tumor growth, more than 40 years ago.

The researchers concluded that the high presence of progesterone receptors suggests that progesterone, rather than estrogen, might be a key driver in the growth of these tumors. The study supports the idea that prolonged use of progesterone-based drugs like Depo Provera may significantly increase the risk of meningiomas, a concern that should have been recognized as far back as 1983.

In 1991, a study in the Journal of Neurosurgery explored the effects of mifepristone, an anti-progesterone agent, on meningiomas. Mifepristone competes with progesterone for binding to progesterone receptors, thereby inhibiting the action of progesterone on tumor cells.

The research found that mifepristone effectively reduced the growth of meningiomas, which are brain tumors known to express a high density of progesterone receptors. By blocking progesterone from binding to its receptors, mifepristone hindered the hormone’s ability to stimulate tumor growth. This discovery provided compelling evidence that progesterone plays a central role in promoting the growth of meningiomas, especially in tumors sensitive to hormonal changes.

The study’s findings had significant clinical implications that should have raised concerns. The research demonstrated that hormone-blocking treatments could serve as a viable therapeutic option for managing meningiomas. It was a breakthrough that could have fundamentally altered how these tumors were treated. This research highlighted the potential of anti-progesterone therapies like mifepristone to regress tumor growth, particularly in cases where progesterone was a contributing factor.

If blocking progesterone could significantly reduce tumor growth, why weren’t pharmaceutical companies prioritizing the potential consequences of increasing progesterone? It seems evident that the synthetic progesterone in Depo-Provera might stimulate meningioma development. This finding, along with a 1990 study, supports the argument that Depo-Provera could cause or exacerbate meningiomas, strengthening the causation claim in these lawsuits.

Meningioma Brain Tumors

A meningioma is a type of brain tumor that develops in the protective membranes covering the brain. Meningiomas are the most common type of brain tumor, accounting for 40% of all reported brain tumors.

Most meningiomas are non-cancerous, but some can be cancerous. These tumors typically grow slowly and may exist for years without causing symptoms.

Meningiomas are categorized into three grades:

• Grade I: Non-cancerous, slow-growing, and accounting for 80% of cases.
• Grade II: Non-cancerous but faster-growing, making treatment more challenging. These atypical tumors include subtypes like atypical, clear cell, and chordoid meningiomas, which exhibit cellular changes that increase recurrence risk and may require both surgery and radiation. While they make up about 15% of meningiomas, over 25% of the calls Nguyen Injury Lawyer has received so far have been Grade II meningioma brain tumors.
• Grade III: Malignant (cancerous), fast-growing, and comprising less than 2% of cases.

Meningiomas are often first detected via MRI scans, sometimes incidentally in patients without symptoms. In such cases, doctors may monitor the tumor rather than immediately operate. If surgery is necessary, the goal is to remove the entire tumor and some surrounding tissue to prevent recurrence. Surgery is the primary treatment for spinal meningiomas and usually has good outcomes with a low recurrence risk. Advances in imaging and surgical techniques have improved the safety and effectiveness of the process.

Treatment for symptomatic intracranial meningiomas typically involves a craniotomy, a highly invasive brain surgery where a portion of the skull is removed to access the brain and meninges. Complete tumor removal can be risky due to the tumor’s location, often requiring additional treatments like radiation or chemotherapy. Key risk factors include superficial meningiomas, moderate to severe peritumoral edema, involvement of critical peritumoral veins, and WHO grade II-III meningiomas.

Studies indicate that patients often experience postoperative anxiety and depression, leading to increased use of sedatives and antidepressants during recovery. Additionally, surgery for intracranial meningioma may trigger seizures, necessitating epilepsy medications (which often come with their own risks). Meningiomas associated with progesterone-based contraceptives typically occur at the skull base, making removal more complex and increasing the risk of complications.

Given the complexity and severity of treatment, as well as the potential for long-term neurological complications, Nguyen Injury Lawyer anticipates significant settlement payouts for these claims if the litigation is successful, particularly for all three grades of meningiomas.

Depo-Provera Product Liability Lawsuits

Pharmaceutical companies like Pfizer have a legal obligation to ensure their products are reasonably safe and to provide clear warnings about known or foreseeable risks. Under the doctrine of strict liability for failure to warn, a manufacturer can be held liable even if the drug isn’t defectively designed, as long as it failed to adequately inform patients and prescribers about serious side effects.

This duty is fundamental. Physicians and patients rely on accurate safety information to weigh a drug’s benefits against its risks. Incomplete or absent warnings prevent informed medical decisions. A drug’s label must disclose all risks known or that should have been known through reasonable diligence.

In the case of Depo-Provera, U.S. labeling failed to disclose the meningioma risk, despite decades of scientific literature and regulatory warnings abroad pointing to this association. Lawsuits now pending will argue that Pfizer was aware—or should have been—of the elevated risk and that its decision not to update the label constitutes a clear failure to warn.

Had the company disclosed the meningioma risk, sales would likely have declined. Patients could have chosen safer contraceptive options, and healthcare providers would have been more cautious in prescribing Depo-Provera, especially for long-term use. Greater transparency could have fundamentally changed the risk-benefit assessment for countless women.

Who Is Eligible to File a Depo Provera Lawsuit?

Nguyen Injury Lawyer is seeking to represent women who received at least two Depo-Provera injections and were subsequently diagnosed with a meningioma (or other type of brain tumor). These are our firm’s minimum eligibility criteria, as discussed in our October 11 update.

Women who used Depo-Provera for extended periods will likely have stronger claims than those with limited use, indicating a dose-response relationship. However, it is believed that receiving the shot at least twice is sufficient to establish a viable claim.

If you meet these criteria and are interested in pursuing a Depo-Provera lawsuit, please contact Nguyen Injury Lawyer at XXX-XXX-XXXX or through our website at https://www.nguyeninjurylawyer.com to discuss your case. You can also reach us via our contact page at https://www.nguyeninjurylawyer.com/contact.

Why Pfizer Could Face Significant Liability in Depo-Provera Lawsuits

As previously mentioned, Pfizer’s potential liability in Depo-Provera lawsuits arises from its alleged failure to adequately warn consumers about the risk of developing meningioma brain tumors.

Drug manufacturers are legally obligated to provide clear warnings about any risks associated with their products. However, in the case of Depo-Provera, it’s alleged that Pfizer omitted the risk of meningiomas from the warning label, despite growing evidence linking long-term use of the shot to this serious condition. Patients rely on receiving complete information when making decisions about their health.

The connection between progesterone and meningiomas has been known, or should have been known, for many years, especially by pharmaceutical companies like Pfizer. These companies are responsible for conducting FDA-mandated post-market surveillance to monitor their products for potential safety concerns.

This alleged failure to warn could expose Pfizer to substantial financial liability in product liability lawsuits. Plaintiffs in Depo Provera meningioma lawsuits will argue that they would have made a different, more informed decision about using the contraceptive if they had been properly informed about the tumor risk. This is a compelling argument. By allegedly failing to update the label, Pfizer may be portrayed as prioritizing profits over patient safety. If a jury accepts this argument, it will likely influence both their perceptions and potential settlement amounts in the Depo shot litigation.

It’s crucial to remember the seriousness of the injuries, and the fear of those injuries, in this litigation. There are numerous birth control options available. Why choose one that could potentially cause a brain tumor? Our lawyers at Nguyen Injury Lawyer believe this litigation will differ from other birth control lawsuit settlements precisely because the injury is so frightening.

Depo-Provera Brain Tumor Lawsuit Settlement Amounts

Any attempt to project settlement amounts for Depo Provera lawsuits requires some initial caveats. It is still early in this litigation to provide an accurate estimate of potential settlement compensation for Depo-Provera brain tumor cases.

Currently, it remains uncertain whether the scientific evidence will be admissible. However, Nguyen Injury Lawyer can offer an educated guess based on certain assumptions and settlement payouts in similar tort cases involving comparable facts and injuries.

Depo-Provera Settlement Predictions

If the evidence supporting causation is upheld in court, Nguyen Injury Lawyer estimates that Depo-Provera brain tumor cases involving significant complications could result in average settlement payouts ranging from $275,000 to $500,000. This range reflects the varying degrees of severity associated with meningiomas, which can significantly affect the level of compensation awarded to plaintiffs. (This all assumes the hurdle of preemption is overcome.)

How would these figures be affected by the severity of the injury? Our attorneys predict the following tiers:

Predicted Depo Provera Settlement Tiers by Injury Severity

Injury Severity	Description	Estimated Settlement Range
Tier 1 High Severity	Grade III meningioma, malignant or aggressive growth. Brain surgery, radiation, or long-term cognitive or neurological deficits. High risk of recurrence. Permanent disability or life-threatening prognosis.	$650,000 – $1,500,000+
Tier 2 Moderate Severity	Grade II meningioma or symptomatic Grade I tumor requiring surgical removal. Some complications or residual effects. Ongoing monitoring, but no confirmed malignancy.	$300,000 – $650,000
Tier 3 Lower Severity	Small, non-surgical Grade I meningioma. Diagnosed during imaging, the condition was monitored but not removed. Minimal or no treatment required. No long-term disability or cognitive impact.	$150,000 – $300,000
Tier 4 Minimal Injury	Incidental finding of an asymptomatic tumor with no clear medical impact. Watch-and-wait approach, no treatment or progression. Strongest cases likely to be prioritized.	Under $150,000

Note: These projected settlement amounts are based on our lawyers’ predictions at a very early stage of the litigation. These predictions may be too optimistic. This also assumes plaintiffs prevail against preemption and other legal challenges Pfizer may bring. As more data becomes available and bellwether trials are scheduled, these numbers are subject to change.

The significant gap between Tier 1 and Tier 4 reflects the substantial differences in symptoms, prognosis, and treatment options between a Grade I (non-cancerous) meningioma and a malignant Grade III meningioma. A Grade III meningioma is potentially life-threatening and very serious, while Grade I meningiomas are generally less damaging and usually not life-threatening.

Grade III meningiomas often grow aggressively, require invasive treatment such as surgery and radiation, and carry a much higher risk of recurrence and poor outcomes. From a litigation standpoint, patients who developed a high-grade brain tumor, such as a Grade III meningioma, after long-term Depo-Provera use may be entitled to significantly higher settlement compensation due to the devastating impact and long-term disability caused by these aggressive tumors.

It is currently unknown how many cases will fall into each of these categories. However, our attorneys at Nguyen Injury Lawyer believe that Grade III depo shot cases will warrant significant compensation. The trial value of those brain cancer lawsuits – the average settlement – could potentially reach tens of millions of dollars.

In the event of a global settlement, average payouts may not reach that level, but these will still be significant cases. Some of them could settle for well over $1 million if this litigation unfolds as anticipated.

It’s also important to consider that the defendant is Pfizer, a company with a market value exceeding $150 billion. The company has substantial COVID-related profits and can afford to pay global settlements in the billions without significant financial strain. This is a significant factor. Nguyen Injury Lawyer is involved in several mass tort lawsuits where the defendant’s financial capacity becomes a relevant consideration. This is not an issue in Depo-Provera lawsuits against Pfizer.

Other Meningioma Lawsuits Provide Insights into Settlement Compensation

A study of meningioma lawsuits offers insight into how lawyers and juries assess the severity of these injuries. The average payout for plaintiffs in these cases exceeded $3 million, with neurosurgery-related claims resulting in the highest settlements.

Therefore, if attorneys like those at Nguyen Injury Lawyer can successfully establish a strong link between Depo-Provera and meningiomas, the potential damages awarded could also be substantial.

How Might a Depo-Provera Settlement Potentially Take Shape?

What might a Depo Provera settlement look like? While it is early to discuss settlement specifics, women considering a Depo Provera lawsuit naturally want to understand the process and potential requirements for reaching a settlement.

There is a centralized “class action” type lawsuit for Depo Provera meningioma lawsuits in the Middle District of Florida. The litigation is officially progressing under a coordinated structure. This MDL enables plaintiffs from across the country to consolidate their cases against Pfizer, focusing on common issues such as the company’s alleged failure to adequately warn about the risk of brain tumors associated with long-term Depo Provera use. There may also be active state court dockets in locations such as Pennsylvania, California, and Illinois.

Although it is still early and bellwether trials have not yet been scheduled, plaintiffs understandably want to know what kind of Depo Provera lawsuit settlement amounts might eventually be possible. If this litigation follows the pattern of other mass torts involving pharmaceutical injuries, here is what you can likely expect:

• Tiered Compensation: Settlement payouts in the Depo Provera MDL will almost certainly be structured in tiers. Women diagnosed with meningiomas requiring brain surgery will likely fall into the highest payout category, while those with smaller or asymptomatic tumors may qualify for lower settlement amounts.
• Estimated Ranges: Similar mass torts suggest potential settlement values could range between $150,000 and $800,000, depending on the severity of the diagnosis, treatment, and long-term impact on quality of life.
• What You Will Need to Do: Few, if any, claimants in this MDL will proceed to court. Plaintiffs’ lawyers will handle much of the work, including collecting and submitting medical records and proof of diagnosis. However, clients must still cooperate and respond to basic document requests.
• Bellwether Trials and Leverage: Once the first few bellwether trials are held (likely in the latter part of 2026), the results will influence Pfizer’s willingness to settle. High jury awards or the emergence of damaging evidence during discovery would give Pfizer a strong incentive to settle to avoid further adverse verdicts.

This litigation is still developing, but the centralized MDL in Florida represents a significant step forward. Women injured by long-term Depo Provera use now have a coordinated path toward compensation, and as more cases are filed, the pressure on Pfizer will likely increase.

Who Are the Possible Defendants in a Depo Shot Lawsuit?

The following are the key potential defendants in a Depo Provera meningioma lawsuit:

• Pfizer Inc.: As the primary defendant, Pfizer holds the New Drug Application (NDA) for Depo-Provera and is responsible for the drug’s labeling and safety information. Pfizer has maintained control over Depo-Provera’s production and labeling since acquiring Pharmacia & Upjohn in 2002. Pfizer is undoubtedly the primary target defendant due to its substantial financial resources and responsibility for the drug’s safety.
• Viatris Inc.: Formed after the merger of Upjohn, Greenstone, and Mylan N.V. in 2020, Viatris is accused of participating in the distribution and sale of Depo-Provera and its “authorized generic” versions.
• Greenstone, LLC: As a Pfizer subsidiary acting as an “authorized generic” distributor, Greenstone allegedly produced and distributed Depo-Provera without brand labeling, but with a chemical composition identical to the branded version.
• Prasco Labs: Another “authorized generic” distributor, Prasco allegedly marketed Depo-Provera as a generic product without altering its chemical composition or labeling. Prasco obtained the exclusive license to distribute the authorized generic version of Depo-Provera—manufactured by Pfizer, the brand-name producer—in November 2020. This transition followed an FTC-mandated divestiture of Pfizer’s Greenstone subsidiary, which had previously handled the distribution of the authorized generic. Prasco asserts that numerous lawsuits in which it is named as a defendant involve Depo-Provera use that concluded before its involvement in distribution began in November 2020.
• Pharmacia & Upjohn: As the original NDA holder for Depo-Provera, acquired by Pfizer, this entity is accused of failing to address safety issues with Depo-Provera before the acquisition.

Proof Needed for a Depo Provera Lawsuit

Individuals who qualify for a Depo-Provera brain tumor lawsuit will ultimately need to prove two key facts to support their claim: (1) that they used the Depo-Provera birth control shot, and (2) that they were diagnosed with meningioma or another type of brain tumor.

If you believe you have a case, contact Nguyen Injury Lawyer today at XXX-XXX-XXXX or visit our website at https://www.nguyeninjurylawyer.com to discuss your legal options. You can also reach us via our contact page: https://www.nguyeninjurylawyer.com/contact.

Proving Your Depo-Provera Case

Evidence of Depo-Provera use can be established through medical records from the prescribing physician. Insurance billing records also serve as documentation of the birth control shot’s use. Furthermore, medical records confirming a meningioma diagnosis are crucial.

At Nguyen Injury Lawyer, our attorneys will assist you in compiling this evidence. We focus on gathering and presenting proof to build the strongest case possible. This involves a comprehensive investigation, consulting with medical experts, and addressing any gaps in the evidence.

Depo-Provera Statute of Limitations

In Depo-Provera litigation, plaintiffs may have more time to file a lawsuit than initially assumed. In many states, claims exceeding ten years might still overcome statute of limitations concerns due to the application of the discovery rule and equitable tolling.

The statute of limitations sets a legal deadline for filing a lawsuit. In product liability cases like those involving Depo-Provera, this deadline typically begins when the injury occurs. However, many individuals only discover the link between their symptoms and the drug after some time, due to delayed effects or a lack of awareness regarding the risks involved, which is a key aspect of the Depo-Provera litigation.

Discovery Rule

The discovery rule stipulates that the statute of limitations begins when the plaintiff discovers, or reasonably should have discovered, both the injury and its potential cause. In Depo-Provera cases, plaintiffs can argue that they couldn’t reasonably connect their drug use to meningioma until a warning was issued, which has not yet occurred.

Equitable Tolling of the Statute of Limitations

Besides the discovery rule, equitable tolling can extend the filing deadline if the defendant’s actions or concealment delayed the plaintiff’s awareness of the injury’s cause. Lawsuits against Pfizer for Depo-Provera will likely invoke equitable tolling, alleging that the company intentionally withheld information about the drug’s risks. Plaintiffs may argue that Pfizer:

• Willfully withheld warnings and safety instructions from the public and healthcare providers regarding the potential dangers of long-term Depo-Provera use, specifically the risk of intracranial meningiomas.
• Actively misrepresented Depo-Provera as safe for its intended use, distributing labeling and promotional materials that downplayed or omitted safety risks, particularly regarding long-term use.

Plaintiffs’ attorneys will likely use equitable tolling based on these alleged actions by Pfizer, arguing that the statute of limitations should be paused due to the deliberate concealment of essential safety information, including knowledge from studies on progestin’s effect on meningiomas. Regulations like 21 C.F.R. § 201.80(e) and 21 C.F.R. § 314.70(c)(6)(iii)(A) mandate that drug manufacturers disclose risks and update warnings. Lawsuits claim Pfizer failed to do so, contributing to the delayed awareness among patients and doctors alike.

Estoppel

Finally, due to Pfizer’s alleged intentional concealment of risks, plaintiffs may argue that Pfizer is estopped from using the statute of limitations as a defense. Plaintiffs contend that Pfizer’s omissions and misrepresentations about Depo Provera’s risks misled them and the medical community, preventing timely discovery of the connection between Depo Provera and meningioma. In essence, this legal doctrine enables victims’ lawyers to argue that Pfizer’s conduct renders any attempt to dismiss their claims based on statutory deadlines invalid.

Contact Nguyen Injury Lawyer About a Depo-Provera Lawsuit

If you used Depo-Provera and were later diagnosed with a meningioma or another type of brain tumor, please contact Nguyen Injury Lawyer today for a free consultation. You can reach us at XXX-XXX-XXXX or through our online contact form.